I believe some really good science, that people can readily

New Post Public Reply Private Reply Replies (0) Message Board
grow
607
I believe some really good science, that people can readily understand, is coming CYDY's way. Other Covid19 trials have recently shown mortality around 30% or above in the SOC arm of their trials, and with CYDY implying an approximate 22% mortality rate for their SOC arm & treatment arm combined, things look very positive for Vyrologix to me. My expectation is that there will be a very helpful reduction in mortality shown in this CYDY trial's primary endpoint.

Next I'd like to mention that the open label extension, the continuing eIND's, the Philippines allocation, and the Medicare billing code give me comfort while we await results from CD12.

Of course I'd like to have heard results already, however I remind myself that good results will validate a drug that will disrupt the field of medicine. I try to maintain patience for all involved that are making sure they have a strong data set, so that they can best present a beautiful new tool to the world. I do also believe that at some point before we hear results, I expect the CEO will be working a lot of deals for production and distribution.

I expect a maximum of 28 day data from this trial, since as far as I know, observations past 28 days were never added to the official endpoints. For simplicity's sake and also for expediting timelines to approval, I believe they made a choice to stick to the max 28 day endpoints.

The current silence I think won't last much longer. All IMHO.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

NextPlat Adjusts E-Commerce Goals Amid Trade Struggles

Updated Category News Views 129

Understanding NextPlat's Recent E-Commerce Adjustments NextPlat Corp (NASDAQ: NXPL), a global leader in e-commerce solutions, has announced critical changes to its operations as a response to the evolving trade landscape between the United States and China. The company anticipates that the recently imposed tariffs will significantly affect its ability to sell...

Continue Reading
Join the Exciting JiggAerobics Event for a Healthier You

Updated Category News Views 372

Join the Exciting JiggAerobics Event for a Healthier You Northeast Delta Human Services Authority (NEDHSA) is thrilled to announce its upcoming JiggAerobics event, now in its seventh installment. This lively gathering aims to promote health and fitness among people of all ages, offering a blend of fun and physical activity. Details of the Event The JiggAerobics event is...

Continue Reading
Key Insights from VanEck's Updated UK Prospectus for Investors

Updated Category News Views 172

VanEck UCITS ETFs plc: Comprehensive Prospectus Overview VanEck UCITS ETFs plc has recently issued a consolidated prospectus aimed at investors in the United Kingdom. This valuable document consolidates insights from earlier prospectus editions and offers a detailed guide into the company's shares. The consolidated prospectus serves as a transparent resource for...

Continue Reading
FirstFarms A/S Faces Challenges Amid FMD Outbreaks in Q1 Report

Updated Category News Views 148

FirstFarms A/S Reports Q1 Challenges Overview of FirstFarms' Financial Performance FirstFarms' financial results for the first quarter reveal unexpected challenges that have significantly influenced its operational landscape. The company faced notably low pig prices at the quarter's onset, accompanied by a disturbing outbreak of foot and mouth disease (FMD) affecting its...

Continue Reading
Shake Shack Reports Impressive Q4 Results Amid Expansion Plans

Updated Category News Views 236

Shake Shack's Fourth Quarter Performance Shake Shack, Inc. (NYSE: SHAK) has reported a remarkable fourth quarter, demonstrating resilience and notable growth in its financial performance. The company achieved an adjusted earnings per share of 26 cents, surpassing analysts’ expectations, which were set at 24 cents. Sales Growth and Financial Highlights During this...

Continue Reading